Presentation of Strong Preclinical Dataset: On September 25, 2024, HOOKIPA presented the preclinical proof-of-concept dataset ...

All presentations and supplemental materials will be available under the Investor Relations section of Aviat's website following the event. Gilead Sciences, Inc. announced today that its executives ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief ...

DaVita Inc. today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason ... 12 at approximately 2:45 p.m. Pacific Time.... Gilead ...

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the ...

The late-breaking poster: Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic ...

Their study was part of a grant run out of the University of Alabama in partnership with UNC, the Vanderbilt University School of Medicine and pharmaceutical company Gilead Sciences ... senior vice ...

FOSTER CITY, Calif., November 08, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy ...

Gilead Sciences (GILD) has been one of the most searched-for stocks ... A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that ...